# SARS-CoV-2 inactivation testing: interim report

<table>
<thead>
<tr>
<th>Report identifier</th>
<th>HCM/CoV2/019/v3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Report date</td>
<td>10 July 2020</td>
</tr>
</tbody>
</table>

Undertaken by High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England

N.B. This is an interim report and may be updated as further results are obtained

## Product/treatment details

<table>
<thead>
<tr>
<th>Product/treatment</th>
<th>GITC 4M Transport Medium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Oxoid/Thermo Fisher Scientific</td>
</tr>
<tr>
<td>Product code</td>
<td>GITC4M</td>
</tr>
<tr>
<td>Composition of product, as supplied</td>
<td>31.8% Guanidinium thiocyanate 2.0% Triton X-100 0.5% Tris 0.6% EDTA</td>
</tr>
<tr>
<td>Manufacturer’s recommended ratio of sample to product</td>
<td>Not known</td>
</tr>
</tbody>
</table>

## Sample details

<table>
<thead>
<tr>
<th>Sample type tested</th>
<th>Tissue culture fluid containing 5% (v/v) foetal calf serum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virus strain tested</td>
<td>SARS-CoV-2 England 2</td>
</tr>
<tr>
<td>Ratio of spiked virus stock to sample matrix</td>
<td>Not applicable; tissue culture fluid used undiluted</td>
</tr>
</tbody>
</table>

## Experimental conditions

<table>
<thead>
<tr>
<th>Ratio of sample to product tested</th>
<th>1 volume sample to 10 volumes product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact times</td>
<td>30 minutes</td>
</tr>
<tr>
<td>Temperature of incubation</td>
<td>Room temperature</td>
</tr>
</tbody>
</table>
There is no additional text for this page.

<table>
<thead>
<tr>
<th>Brief description of tests performed</th>
<th><strong>Test 1 and 2:</strong> Triplicate samples were treated with test buffer for indicated contact time/s or mock-treated in triplicate with an equivalent volume of PBS. All samples were then subjected to a purification step to remove cytotoxic buffer components. PBS-treated samples were subjected to the same purification procedure in parallel. Purified samples were immediately titrated on Vero E6 cells to establish virus titre (<strong>test 1</strong>). This test is quantitative and reports the titre of virus in each treatment condition in TCID50 per ml. Reduction in virus titre following treatment is given as the difference between the mean log_{10} TCID50/ml for treated conditions and the PBS control. In parallel, purified samples were seeded onto Vero E6 monolayers to amplify any remaining virus over the course of up to four serial passages (<strong>test 2</strong>). Virus amplification over each passage was detected by visual (microscopic) examination of monolayers for cytopathic effect, and confirmed by SARS-CoV-2-specific real-time PCR. This test is qualitative and reports either the presence or absence of virus amplification. This test may detect levels of virus that are below the detection limit of the titration assay (<strong>test 1</strong>) due to a greater sample plating volume and the opportunity for any virus present to amplify over serial passages. <strong>Test 3:</strong> 100-fold dilutions of SARS-CoV-2 were spiked into test buffer aliquots and incubated at room temperature. After 0, 4 or 8 days, triplicate samples for each dilution were extracted and subjected to SARS-CoV2-specific real-time PCR. This test indicates stability of SARS-CoV-2 RNA in the test buffer by comparing Ct values for each virus dilution over time. This test measures levels of viral RNA only and does not reflect virus infectivity.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test 1 and 2:</strong> Triplicate samples were treated with test buffer for indicated contact time/s or mock-treated in triplicate with an equivalent volume of PBS. All samples were then subjected to a purification step to remove cytotoxic buffer components. PBS-treated samples were subjected to the same purification procedure in parallel. Purified samples were immediately titrated on Vero E6 cells to establish virus titre (<strong>test 1</strong>). This test is quantitative and reports the titre of virus in each treatment condition in TCID50 per ml. Reduction in virus titre following treatment is given as the difference between the mean log_{10} TCID50/ml for treated conditions and the PBS control. In parallel, purified samples were seeded onto Vero E6 monolayers to amplify any remaining virus over the course of up to four serial passages (<strong>test 2</strong>). Virus amplification over each passage was detected by visual (microscopic) examination of monolayers for cytopathic effect, and confirmed by SARS-CoV-2-specific real-time PCR. This test is qualitative and reports either the presence or absence of virus amplification. This test may detect levels of virus that are below the detection limit of the titration assay (<strong>test 1</strong>) due to a greater sample plating volume and the opportunity for any virus present to amplify over serial passages. <strong>Test 3:</strong> 100-fold dilutions of SARS-CoV-2 were spiked into test buffer aliquots and incubated at room temperature. After 0, 4 or 8 days, triplicate samples for each dilution were extracted and subjected to SARS-CoV2-specific real-time PCR. This test indicates stability of SARS-CoV-2 RNA in the test buffer by comparing Ct values for each virus dilution over time. This test measures levels of viral RNA only and does not reflect virus infectivity.</td>
<td></td>
</tr>
</tbody>
</table>
### Table of results (test 1 and test 2)

<table>
<thead>
<tr>
<th>Maximum detectable virus reduction in Test 1 (log_{10} TCID50/ml)</th>
<th>5.3†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test 1:</strong> Virus titration post-treatment</td>
<td><strong>Test 2:</strong> Passage of samples in cell culture</td>
</tr>
<tr>
<td>Mean virus titre (log_{10} TCID50/ml)</td>
<td>Titre reduction (log_{10} TCID50/ml)</td>
</tr>
<tr>
<td>PBS-treated</td>
<td>7.0</td>
</tr>
<tr>
<td>Test buffer-treated</td>
<td>≤1.7†</td>
</tr>
</tbody>
</table>

†Virus titre in undiluted sample could not be determined due to residual buffer toxicity

*Only one passage performed

### Table of results (test 1 and test 2, repeated)

<table>
<thead>
<tr>
<th>Maximum detectable virus reduction in Test 1 (log_{10} TCID50/ml)</th>
<th>5.1†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test 1:</strong> Virus titration post-treatment</td>
<td><strong>Test 2:</strong> Passage of samples in cell culture</td>
</tr>
<tr>
<td>Mean virus titre (log_{10} TCID50/ml)</td>
<td>Titre reduction (log_{10} TCID50/ml)</td>
</tr>
<tr>
<td>PBS-treated</td>
<td>6.8</td>
</tr>
<tr>
<td>Test buffer-treated</td>
<td>≤1.7†</td>
</tr>
</tbody>
</table>

†Virus titre in undiluted sample could not be determined due to residual buffer toxicity

### Table of results (test 3)

| Mean Ct value of samples spiked with increasing dilutions of SARS-CoV-2 (standard deviation) |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Undiluted | 1:10^2 | 1:10^4 | 1:10^6 |
| 0 day treatment | 14.7 (0.2) | 21.8 (0.3) | 28.6 (0.2) | 35.6 (0.9) |
| 4 day treatment | 16.5 (0.2) | 23.9 (0.2) | 30.7 (0.2) | Not detectable (2 replicates) 36.5 (1 replicate) |
| 8 day treatment | 18.5 (0.1) | 25.5 (0.2) | 32.5 (0.6) | Not detectable (all replicates) |
Interpretation

Test 1: Treatment with GITC 4M Transport Medium resulted in a $\geq 5.1 \log_{10}$ reduction in infectious titre in both experiment repeats, the maximum detectable titre reduction in these tests. Levels of infectious virus remaining in undiluted treated samples could not be evaluated due to residual buffer cytotoxicity remaining following sample purification.

Test 2: Infectious virus has not been detected in test 2 after four serial passages in cell culture.

Demonstrating complete inactivation is dependent on the starting titre of virus used for testing. Sample treatments that inactivate virus effectively in our testing may fail to inactivate samples containing higher levels of virus than those evaluated in this study.

These tests have been performed on tissue culture fluid containing 5% (v/v) foetal calf serum. The effectiveness of this treatment against SARS-CoV-2 may vary when used to inactivate clinical samples or other types of sample matrix. Any results of inactivation testing using other sample matrices will be released as they become available.

Test 3: We observed increases in Ct value in SARS-CoV-2 specific real-time PCR following prolonged incubation in this buffer (~2 Ct after 4 days; up to 3.8 Ct after 8 days). At the highest dilution of virus tested, viral RNA became undetectable in some replicates after incubation for 4 days, and was undetectable in all replicates by 8 days. Extended treatment times with this buffer therefore have a detrimental effect on RNA stability.

Inactivation reagents should not be assumed to be 100% effective against SARS-CoV-2.

Suitability of products and treatments for inactivation of other pathogens has not been evaluated in this study.

All COVID-19 laboratory testing workflows must be subjected to suitable and sufficient risk assessment, with consideration given to any inactivation step. Risk assessments should be reviewed regularly as new information on the inactivation of SARS-CoV-2 becomes available.

The impact of chosen inactivation method on the sensitivity of subsequent SARS-CoV-2 detection should also be assessed locally.
Disclaimer

PHE’s evaluations of commercial products and treatments for inactivating SARS-CoV-2 have been carried out primarily for PHE’s own internal use and the reports of such evaluations are shared solely for readers information; PHE does not in any way recommend any particular product for virus inactivation; and PHE shall not be responsible for the choice of product or treatment for virus inactivation, and it is the responsibility of the testing laboratory to ensure that any such product or treatment implemented has undergone the necessary verification and validation; and PHE shall not be liable, to the greatest extent possible under any applicable law, for any claim, loss or damage arising out of or connected with use of this and related reports and choice of virus inactivation products or treatments.

PHE is an Executive Agency of the Department of Health and Social Care. Unauthorised use of the PHE name and/or logo is prohibited.

Summary of revisions

Version 1: New document
Version 2: Reformatted for publication
Version 3: Addition of new data

Queries regarding this report or HCM inactivation testing should be directed to HCMgroup@phe.gov.uk

PHE publications gateway number: GW-1464